search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use.

Andries T Marees ,
Anke R Hammerschlag ,
Lisa Bastarache ,
Hilde de Kluiver ,
Florence Vorspan ,
Wim van den Brink ,
Dirk J Smit ,
Damiaan Denys ,
Eric R Gamazon ,
Ruifang Li-Gao ,
Elemi J Breetvelt ,
Mark C H de Groot ,
Tessel E Galesloot ,
Sita H Vermeulen ,
Jan L Poppelaars ,
Patrick C Souverein ,
Renske Keeman ,
Renée de Mutsert ,
Raymond Noordam ,
Frits R Rosendaal ,
Najada Stringa ,
Dennis O Mook-Kanamori ,
Ilonca Vaartjes ,
Lambertus A Kiemeney ,
Martin den Heijer ,
Natasja M van Schoor ,
Olaf H Klungel ,
Anke H Maitland-Van der Zee ,
Marjanka K Schmidt ,
Tinca J C Polderman ,
Andries R van der Leij ,
Danielle Posthuma ,
Eske M Derks

Abstract

METHODS

We meta-analyzed ExomeChip association results from eight discovery cohorts and included 12,466 subjects and 7432 smokers in the analysis of alcohol consumption and tobacco use, respectively. The ExomeChip interrogates low-frequency and rare exonic variants, and in addition a small pool of common variants. We investigated top variants in an independent sample in which ICD-9 diagnoses of "alcoholism" (N = 25,508) and "tobacco use disorder" (N = 27,068) had been assessed. In addition to the single variant analysis, we performed gene-based, polygenic risk score (PRS), and pathway analyses.

RESULTS

The meta-analysis did not yield exome-wide significant results. When we jointly analyzed our top results with the independent sample, no low-frequency or rare variants reached significance for alcohol consumption or tobacco use. However, two common variants that were present on the ExomeChip, rs16969968 (p = 2.39 × 10-7) and rs8034191 (p = 6.31 × 10-7) located in CHRNA5 and AGPHD1 at 15q25.1, showed evidence for association with tobacco use.

BACKGROUND

Alcohol and tobacco use are heritable phenotypes. However, only a small number of common genetic variants have been identified, and common variants account for a modest proportion of the heritability. Therefore, this study aims to investigate the role of low-frequency and rare variants in alcohol and tobacco use.

DISCUSSION

Low-frequency and rare exonic variants with large effects do not play a major role in alcohol and tobacco use, nor does the aggregate effect of ExomeChip variants. However, our results confirmed the role of the CHRNA5-CHRNA3-CHRNB4 cluster of nicotinic acetylcholine receptor subunit genes in tobacco use.

More about this publication

Drug and alcohol dependence

Volume 188
Pages 94-101
Publication date 01-07-2018

Full text links

Publisher website (DOI) 10.1016/j.drugalcdep.2018.03.026
Europe PubMed Central 29758381
Pubmed 29758381

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.